Treatment of eosinophilic esophagitis: Overview, current limitations, and future direction

Matthew Bohm, Joel E. Richter

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Eosinophilic esophagitis (EE) is an increasingly recognized syndrome presenting with upper gastrointestinal (UGI) symptoms in association with hypereosinophilia (>15 eosinophils/HPF) on esophageal mucosal biopsies. The pathogenesis is unknown, but the candidate etiologies include food and aeroallergen hypersensitivity and an unusual presentation of gastroesophageal reflux disease. This review will highlight the treatments of EE in children and adults. Current treatments are controversial, few data are available in adults, and long-term studies are almost nonexistent. We outline the limitations in the current studies and suggest seven major issues in the study design that must be addressed in future drug trials.

Original languageEnglish (US)
Pages (from-to)2635-2644
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume103
Issue number10
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Eosinophilic Esophagitis
Food Hypersensitivity
Gastroesophageal Reflux
Eosinophils
Biopsy
Therapeutics
Pharmaceutical Preparations
Direction compound

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of eosinophilic esophagitis : Overview, current limitations, and future direction. / Bohm, Matthew; Richter, Joel E.

In: American Journal of Gastroenterology, Vol. 103, No. 10, 10.2008, p. 2635-2644.

Research output: Contribution to journalReview article

@article{da5f5bfea6c6419a825da2484fa27bf9,
title = "Treatment of eosinophilic esophagitis: Overview, current limitations, and future direction",
abstract = "Eosinophilic esophagitis (EE) is an increasingly recognized syndrome presenting with upper gastrointestinal (UGI) symptoms in association with hypereosinophilia (>15 eosinophils/HPF) on esophageal mucosal biopsies. The pathogenesis is unknown, but the candidate etiologies include food and aeroallergen hypersensitivity and an unusual presentation of gastroesophageal reflux disease. This review will highlight the treatments of EE in children and adults. Current treatments are controversial, few data are available in adults, and long-term studies are almost nonexistent. We outline the limitations in the current studies and suggest seven major issues in the study design that must be addressed in future drug trials.",
author = "Matthew Bohm and Richter, {Joel E.}",
year = "2008",
month = "10",
doi = "10.1111/j.1572-0241.2008.02116.x",
language = "English (US)",
volume = "103",
pages = "2635--2644",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Treatment of eosinophilic esophagitis

T2 - Overview, current limitations, and future direction

AU - Bohm, Matthew

AU - Richter, Joel E.

PY - 2008/10

Y1 - 2008/10

N2 - Eosinophilic esophagitis (EE) is an increasingly recognized syndrome presenting with upper gastrointestinal (UGI) symptoms in association with hypereosinophilia (>15 eosinophils/HPF) on esophageal mucosal biopsies. The pathogenesis is unknown, but the candidate etiologies include food and aeroallergen hypersensitivity and an unusual presentation of gastroesophageal reflux disease. This review will highlight the treatments of EE in children and adults. Current treatments are controversial, few data are available in adults, and long-term studies are almost nonexistent. We outline the limitations in the current studies and suggest seven major issues in the study design that must be addressed in future drug trials.

AB - Eosinophilic esophagitis (EE) is an increasingly recognized syndrome presenting with upper gastrointestinal (UGI) symptoms in association with hypereosinophilia (>15 eosinophils/HPF) on esophageal mucosal biopsies. The pathogenesis is unknown, but the candidate etiologies include food and aeroallergen hypersensitivity and an unusual presentation of gastroesophageal reflux disease. This review will highlight the treatments of EE in children and adults. Current treatments are controversial, few data are available in adults, and long-term studies are almost nonexistent. We outline the limitations in the current studies and suggest seven major issues in the study design that must be addressed in future drug trials.

UR - http://www.scopus.com/inward/record.url?scp=53149132781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149132781&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2008.02116.x

DO - 10.1111/j.1572-0241.2008.02116.x

M3 - Review article

C2 - 18721234

AN - SCOPUS:53149132781

VL - 103

SP - 2635

EP - 2644

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -